Effects of tonabersat on migraine with aura: a randomised, double-blind, placebo-controlled crossover study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Effects of tonabersat on migraine with aura: a randomised, double-blind, placebo-controlled crossover study. / Hauge, Anne W; Asghar, Mohammed S; Schytz, Henrik W; Christensen, Karl; Olesen, Jes; Hauge, Anne Werner; Asghar, Mohammad Sohail; Schytz, Henrik W; Christensen, Karl; Olesen, Jes.

I: Lancet Neurology, Bind 8, Nr. 8, 2009, s. 718-23.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Hauge, AW, Asghar, MS, Schytz, HW, Christensen, K, Olesen, J, Hauge, AW, Asghar, MS, Schytz, HW, Christensen, K & Olesen, J 2009, 'Effects of tonabersat on migraine with aura: a randomised, double-blind, placebo-controlled crossover study', Lancet Neurology, bind 8, nr. 8, s. 718-23. https://doi.org/10.1016/S1474-4422(09)70135-8, https://doi.org/10.1016/S1474-4422(09)70135-8

APA

Hauge, A. W., Asghar, M. S., Schytz, H. W., Christensen, K., Olesen, J., Hauge, A. W., ... Olesen, J. (2009). Effects of tonabersat on migraine with aura: a randomised, double-blind, placebo-controlled crossover study. Lancet Neurology, 8(8), 718-23. https://doi.org/10.1016/S1474-4422(09)70135-8, https://doi.org/10.1016/S1474-4422(09)70135-8

Vancouver

Hauge AW, Asghar MS, Schytz HW, Christensen K, Olesen J, Hauge AW o.a. Effects of tonabersat on migraine with aura: a randomised, double-blind, placebo-controlled crossover study. Lancet Neurology. 2009;8(8):718-23. https://doi.org/10.1016/S1474-4422(09)70135-8, https://doi.org/10.1016/S1474-4422(09)70135-8

Author

Hauge, Anne W ; Asghar, Mohammed S ; Schytz, Henrik W ; Christensen, Karl ; Olesen, Jes ; Hauge, Anne Werner ; Asghar, Mohammad Sohail ; Schytz, Henrik W ; Christensen, Karl ; Olesen, Jes. / Effects of tonabersat on migraine with aura: a randomised, double-blind, placebo-controlled crossover study. I: Lancet Neurology. 2009 ; Bind 8, Nr. 8. s. 718-23.

Bibtex

@article{014b8970ad9a11debc73000ea68e967b,
title = "Effects of tonabersat on migraine with aura: a randomised, double-blind, placebo-controlled crossover study",
abstract = "BACKGROUND: Migraine with aura is thought likely to be caused by cortical spreading depression (CSD). Tonabersat inhibits CSD, and we therefore investigated whether tonabersat has a preventive effect in migraine with aura. METHODS: In this randomised, double-blind, placebo-controlled crossover trial, 40 mg tonabersat once daily was compared with matched placebo in patients who had at least one aura attack per month during the past 3 months. Randomisation was by computer-generated list. Patients kept a detailed diary to enable objective diagnosis of each attack as migraine with aura, migraine without aura, or other type of headache. Primary endpoints were a reduction in aura attacks with or without headache and a reduction in migraine headache days with or without an aura. Analysis was per protocol. This trial is registered, number NCT00332007. FINDINGS: 39 patients were included in the study, of whom 31 were included in the statistical analysis of efficacy. Median (IQR) attacks of aura were reduced from 3.2 (1.0-5.0) per 12 weeks on placebo to 1.0 (0-3.0) on tonabersat (p=0.01), whereas the other primary outcome measure, median migraine headache days with or without aura, was not significantly different between placebo and tonabersat groups (3.0 days in each group; p=0.09). Tonabersat was well tolerated but overall had more side-effects than placebo. INTERPRETATION: Tonabersat showed a preventive effect on attacks of migraine aura but no efficacy on non-aura attacks, in keeping with its known inhibitory effect on CSD. The results support the theory that auras are caused by CSD and that this phenomenon is not involved in attacks without aura. FUNDING: Minster Pharmaceuticals; Lundbeck Foundation.",
author = "Hauge, {Anne W} and Asghar, {Mohammed S} and Schytz, {Henrik W} and Karl Christensen and Jes Olesen and Hauge, {Anne Werner} and Asghar, {Mohammad Sohail} and Schytz, {Henrik W} and Karl Christensen and Jes Olesen",
note = "Keywords: Adult; Aged; Benzamides; Benzopyrans; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Migraine with Aura; Treatment Outcome; Young Adult",
year = "2009",
doi = "10.1016/S1474-4422(09)70135-8",
language = "English",
volume = "8",
pages = "718--23",
journal = "Lancet Neurology",
issn = "1474-4422",
publisher = "TheLancet Publishing Group",
number = "8",

}

RIS

TY - JOUR

T1 - Effects of tonabersat on migraine with aura: a randomised, double-blind, placebo-controlled crossover study

AU - Hauge, Anne W

AU - Asghar, Mohammed S

AU - Schytz, Henrik W

AU - Christensen, Karl

AU - Olesen, Jes

AU - Hauge, Anne Werner

AU - Asghar, Mohammad Sohail

AU - Schytz, Henrik W

AU - Christensen, Karl

AU - Olesen, Jes

N1 - Keywords: Adult; Aged; Benzamides; Benzopyrans; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Migraine with Aura; Treatment Outcome; Young Adult

PY - 2009

Y1 - 2009

N2 - BACKGROUND: Migraine with aura is thought likely to be caused by cortical spreading depression (CSD). Tonabersat inhibits CSD, and we therefore investigated whether tonabersat has a preventive effect in migraine with aura. METHODS: In this randomised, double-blind, placebo-controlled crossover trial, 40 mg tonabersat once daily was compared with matched placebo in patients who had at least one aura attack per month during the past 3 months. Randomisation was by computer-generated list. Patients kept a detailed diary to enable objective diagnosis of each attack as migraine with aura, migraine without aura, or other type of headache. Primary endpoints were a reduction in aura attacks with or without headache and a reduction in migraine headache days with or without an aura. Analysis was per protocol. This trial is registered, number NCT00332007. FINDINGS: 39 patients were included in the study, of whom 31 were included in the statistical analysis of efficacy. Median (IQR) attacks of aura were reduced from 3.2 (1.0-5.0) per 12 weeks on placebo to 1.0 (0-3.0) on tonabersat (p=0.01), whereas the other primary outcome measure, median migraine headache days with or without aura, was not significantly different between placebo and tonabersat groups (3.0 days in each group; p=0.09). Tonabersat was well tolerated but overall had more side-effects than placebo. INTERPRETATION: Tonabersat showed a preventive effect on attacks of migraine aura but no efficacy on non-aura attacks, in keeping with its known inhibitory effect on CSD. The results support the theory that auras are caused by CSD and that this phenomenon is not involved in attacks without aura. FUNDING: Minster Pharmaceuticals; Lundbeck Foundation.

AB - BACKGROUND: Migraine with aura is thought likely to be caused by cortical spreading depression (CSD). Tonabersat inhibits CSD, and we therefore investigated whether tonabersat has a preventive effect in migraine with aura. METHODS: In this randomised, double-blind, placebo-controlled crossover trial, 40 mg tonabersat once daily was compared with matched placebo in patients who had at least one aura attack per month during the past 3 months. Randomisation was by computer-generated list. Patients kept a detailed diary to enable objective diagnosis of each attack as migraine with aura, migraine without aura, or other type of headache. Primary endpoints were a reduction in aura attacks with or without headache and a reduction in migraine headache days with or without an aura. Analysis was per protocol. This trial is registered, number NCT00332007. FINDINGS: 39 patients were included in the study, of whom 31 were included in the statistical analysis of efficacy. Median (IQR) attacks of aura were reduced from 3.2 (1.0-5.0) per 12 weeks on placebo to 1.0 (0-3.0) on tonabersat (p=0.01), whereas the other primary outcome measure, median migraine headache days with or without aura, was not significantly different between placebo and tonabersat groups (3.0 days in each group; p=0.09). Tonabersat was well tolerated but overall had more side-effects than placebo. INTERPRETATION: Tonabersat showed a preventive effect on attacks of migraine aura but no efficacy on non-aura attacks, in keeping with its known inhibitory effect on CSD. The results support the theory that auras are caused by CSD and that this phenomenon is not involved in attacks without aura. FUNDING: Minster Pharmaceuticals; Lundbeck Foundation.

U2 - 10.1016/S1474-4422(09)70135-8

DO - 10.1016/S1474-4422(09)70135-8

M3 - Journal article

VL - 8

SP - 718

EP - 723

JO - Lancet Neurology

JF - Lancet Neurology

SN - 1474-4422

IS - 8

ER -

ID: 14828817